Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease

NCT07571161 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: Donanemab
DRUG: Placebo

Sponsor

Eli Lilly and Company